Stockscreener 앱 받기
47.64
9.92%
4.30
시간 외 거래:
49.94
2.30
+4.83%
전일 마감가:
$43.34
열려 있는:
$46.37
하루 거래량:
36.01M
Relative Volume:
1.64
시가총액:
$211.69B
수익:
$46.77B
순이익/손실:
$15.45B
주가수익비율:
13.74
EPS:
3.468
순현금흐름:
$4.40B
1주 성능:
-19.84%
1개월 성능:
-15.32%
6개월 성능:
+4.98%
1년 성능:
-45.35%
1일 변동 폭
$45.84
$47.74
1주일 범위
$43.24
$59.30
52주 변동 폭
$43.08
$93.80
노보 노디스크 Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, MRK, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
47.64 | 192.59B | 46.77B | 15.45B | 4.40B | 3.468 |
|
LLY
Lilly Eli Co
|
1,058.18 | 913.67B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
239.99 | 572.91B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.43 | 387.09B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
MRK
Merck Co Inc
|
121.93 | 297.22B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
AZN
Astrazeneca Plc
|
193.03 | 290.15B | 58.07B | 9.40B | 9.87B | 3.0115 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Neutral |
| 2025-12-08 | 다운그레이드 | Argus | Buy → Hold |
| 2025-10-27 | 재개 | Jefferies | Underperform |
| 2025-10-01 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-09-29 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-09-16 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore - The Motley Fool
Ozempic Maker Novo Nordisk Flags Declining Sales In 2026 - Sahm
Novo Nordisk Faces a Sales Decline in 2026, But Its Portfolio and Pipeline Provide Long-Term Growth - morningstar.com
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Novo Nordisk ADR earnings beat by $0.10, revenue topped estimates - Investing.com Australia
Novo Nordisk's U.S. listing drops significantly after earnings report - medwatch.com
Novo Nordisk A/S (NVO): A Bull Case Theory - Finviz
Jim Cramer Believes Novo Nordisk "Is a Hold, Not a Buy" - Finviz
Is Novo Nordisk Stock a Bargain Right Now? - Finviz
BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures - Finviz
Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? - Finviz
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? - Finviz
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? - Finviz
5 Stocks To Keep an Eye On in 2026, According to Experts - AOL.com
Novo Nordisk’s Wegovy Pill And Akero Deal Reframe Obesity Growth Story - Sahm
Market Trends: What is the next catalyst for ISPCRate Cut & Weekly Setup with ROI Potential - baoquankhu1.vn
Stock Report: Is Novo Nordisk A s b Shares Adrhedged in a consolidation phaseJuly 2025 Highlights & Real-Time Sentiment Analysis - baoquankhu1.vn
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus
Jim Cramer on Novo Nordisk: "I Think They're Making a Turn Here" - Finviz
Novo Nordisk ADR: Weight?loss Champion Faces High?Altitude Turbulence - AD HOC NEWS
Novo Nordisk Deepens Cell Therapy Push In Canada As Shares Screen Cheap - Sahm
Key facts: Novo Nordisk stock rises 9.12%; expands diabetes partnership; launches Ozempic ad campaign - TradingView
Is Oral Wegovy a Game Changer for Novo Nordisk? - Finviz
Novo Nordisk A/S-Spons ADR (NYSE:NVO) Demonstrates a Strong Dividend Profile Backed by High Profitability - Chartmill
Shorts Report: Can Novo Nordisk A s b Shares Adrhedged be the next market leader - baoquankhu1.vn
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? - Finviz
Novo Nordisk (NVO) is "in a Battle," Says Jim Cramer - Finviz
Europe’s ADR Index Was Flat, But Single Stocks Were Not - Finimize
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.49%
자본화:
|
볼륨(24시간):